2,3-dimethyl-2,3-dihydro-benzofuran | 42740-74-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 英文名称: 2,3-dimethyl-2,3-dihydro-benzofuran
• 英文别名: 2,3-Dimethyl-2,3-dihydrobenzofuran；2,3-Dimethyl-cumaran；2,3-dimethyl-2,3-dihydro-1-benzofuran
• CAS: 42740-74-9
• 化学式: C₁₀H₁₂O
• 分子量: 148.205
• InChiKey: XHMRRECSXXCOFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,3-dimethyl-2,3-dihydro-benzofuran 在 硫酸 、 硝酸 作用下， 生成 2,3-二甲基-5,7-二硝基-2,3-二氢-苯并呋喃
  参考文献：
  名称：

  Nitrocoumarans

  摘要：

  DOI：

  10.1021/ja01550a071
• 作为产物：
  描述：

  2-(but-3-en-2-yl)phenol 在 氢溴酸 、 溶剂黄146 作用下， 生成 2,3-dimethyl-2,3-dihydro-benzofuran
  参考文献：
  名称：

  Claisen; Tietze, Chemische Berichte, 1926, vol. 59, p. 2349

  摘要：

  DOI：

文献信息

• C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF
  申请人：SHANGHAI DE NOVO PHARMATECH CO. LTD.

  公开号：US20170037038A1

  公开（公告）日：2017-02-09

  This invention relates to a kind of C-aryl glycoside derivatives, its pharmaceutical compositions, preparation methods, and uses thereof. The preparation method comprises: method 1: in a solvent, deprotecting the acetyl protecting groups of compound 1-f in the presence of a base; method 2: 1) compound 2-g reacts with via Mitsunobu reaction; 2) deprotecting the acetyl protecting groups of compound 2-f obtained from step 1; method 3: 1) compound 2-g reacts with via nucleophilic substitution reaction; 2) deprotecting the acetyl protecting groups of compound 3-f obtained from step 1. The pharmaceutical composition comprises a kind of C-aryl glycoside derivatives; it's pharmaceutically acceptable salts and/or prodrugs thereof and excipient thereof. This invention further relates to a kind of C-aryl glycoside derivatives, it's pharmaceutically acceptable salts or pharmaceutical compositions thereof for the use in preparation of a SGLT inhibitor. The C-aryl glycoside derivatives of this invention provides a new direction for the study of SGLT inhibitors.

  这项发明涉及一种C-芳基糖苷衍生物，其药物组合物、制备方法及其用途。制备方法包括：方法1：在溶剂中，在碱的存在下去保护化合物1-f的乙酰保护基；方法2：1）化合物2-g通过Mitsunobu反应发生反应；2）去除从步骤1得到的化合物2-f的乙酰保护基；方法3：1）化合物2-g通过亲核取代反应发生反应；2）去除从步骤1得到的化合物3-f的乙酰保护基。药物组合物包括一种C-芳基糖苷衍生物；其药学上可接受的盐和/或前药以及赋形剂。这项发明还涉及一种C-芳基糖苷衍生物，其药学上可接受的盐或其药物组合物，用于制备SGLT抑制剂。这项发明的C-芳基糖苷衍生物为SGLT抑制剂的研究提供了新的方向。
• Dihydrobenzofuran production from catalytic tandem Claisen rearrangement–intramolecular hydroaryloxylation of allyl phenyl ethers in subcritical water
  作者：Ligang Luo、Chunze Liu、Zhiqiang Hou、Yuanyuan Wang、Liyi Dai

  DOI：10.1039/c4ra04689g

  日期：——

  mild method for the preparation of dihydrobenzofurans through hydrothermal catalytic tandem Claisen rearrangement–intramolecular hydroaryloxylation of allyl phenyl ethers. This reaction provides a new method for constructing dihydrobenzofurans, a process that is potentially applicable to natural product synthesis. SBA-15, TS-1, HZSM-5 were chosen as catalysts in a hydrothermal reaction medium between 200

  我们在此报告了一种温和的方法，该方法通过水热催化串联Claisen重排-烯丙基苯基醚的分子内氢芳氧基化来制备二氢苯并呋喃。该反应提供了构建二氢苯并呋喃的新方法，该方法可能适用于天然产物的合成。选择SBA-15，TS-1，HZSM-5作为200-320°C水热反应介质中的催化剂。HZSM-5催化剂表现出最高的催化活性，研究了烯丙基苯基醚-水的摩尔比，时间，压力，温度和催化剂对水热条件下克莱森加氢芳氧基化反应的影响。后两个过程变量对产品的产量和分布影响最大。
• CATALYTIC SCRIABINE REACTION
  申请人：SNOWDEN Roger

  公开号：US20080091042A1

  公开（公告）日：2008-04-17

  The present invention relates to the field of organic synthesis. More particularly it provides a process for making aromatic non-conjugated enol esters or enol ethers from an aromatic compound or moiety and a protected enal compound or moiety, such as an acetal or an acylal. The reaction is promoted by a salt of formula MX 1-4 , M representing a transition metal such as Zn or Fe and X representing a mono-anion, or by BY 3 , wherein Y represents a fluoride or a phenyl group optionally substituted.

  本发明涉及有机合成领域，更具体地提供了一种从芳香化合物或基团和保护的烯醛化合物或基团（例如缩醛或酰缩醛）制备芳香族非共轭烯醇酯或烯醚的方法。该反应由MX1-4的盐催化，其中M表示过渡金属，例如Zn或Fe，X表示单负离子，或由BY3催化，其中Y表示氟化物或苯基（可选择性取代）。
• INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：US20140031277A1

  公开（公告）日：2014-01-30

  The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS 3 -NS 4 A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

  本发明涉及以下式I的化合物：或其药学上可接受的盐或混合物，其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒NS3-NS4A蛋白酶的活性。因此，它们通过干扰丙型肝炎病毒的生命周期发挥作用，并且还可用作抗病毒剂。本发明还涉及包含这些化合物的组合物，无论是用于体外使用还是用于治疗患有HCV感染的患者的给药，并涉及制备这些化合物的过程。本发明还涉及通过给予本发明化合物的组合物来治疗患有HCV感染的患者的方法。本发明还涉及制备这些化合物的过程。
• BENZOXAZINES AS MODULATORS OF ION CHANNELS
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：US20140309220A1

  公开（公告）日：2014-10-16

  The invention relates to benzoxazines useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及苯并噁唑，其可用作离子通道的抑制剂。本发明还提供了包含本发明化合物的药学上可接受的组合物，并提供了使用这些组合物治疗各种疾病的方法。